We optimize biopharmaceutical R&D productivity, commercial value, and patient outcomes through our scalable end-to-end platform integrating biosimulation, regulatory science, and market access solutions.
Our customers include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Since 2014, customers who use Certara’s biosimulation software and technology-enabled services have received over 90% of all new drug and biologic approvals by the FDA.
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
Dec 21, 2021
FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices PRINCETON, N.J. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J. , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates
Certara to Host Investor Day on December 15, 2021
Dec 08, 2021
PRINCETON, N.J. , Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City . Certara’s management team will provide updates on the Company’s strategy,